HLS Therapeutics Inc. announced that it has successfully entered into Product Listing Agreements with New Brunswick, Northwest Territories and the NIHB, for the listing and public reimbursement of Vascepa (icosapent ethyl) on their respective Public Prescription Drug Insurance Plans. All three PLAs are now in effect. Under the terms of the respective PLAs, Vascepa will be reimbursed for the secondary prevention of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with established cardiovascular disease and elevated triglycerides.

As disclosed previously, HLS achieved public reimbursement and a PLA in the province of Quebec in May 2022 and has reimbursement coverage for more than 90% of privately covered lives in Canada that are in-label.